Rafeeq
@rafeeq_rm
Paediatric gastroenterologist, past Chair of IBD WG of BSPGHAN(2017-2020), Past Chair of Education WG of BSPGHAN loves reading, travelling and sports
These cakes were brought by my 18 year old patient with #Crohn’s disease. It was his last appointment at the Children’s Hospital.I have looked after him for~5 years,he is in deep remission. #IBD management is team work. Thx to staff @Bham_Childrens @CrohnsColitisUK @CICRAcharity
Our scoping review on use of Wearable technologies in #IBD now published in @AGA_CGH Suggests increasing role in - early prediction of flares - cytokine/biomarker measurement in sweat - future clinical trials doi.org/10.1016/j.cgh.…
Pleased to share our latest article in @UEGJournal Consensus on upper GI endoscopy KPIs and minimum standards to reduce Post Endoscopy Upper Gastrointestinal Cancer rate @GastroMJB @NJEMCP @abdullahaabbasi @SyedGerdezi @drkeithsiau @PEUGIC_RCA onlinelibrary.wiley.com/doi/10.1002/ue…
Exploring the earnings of @NHSEngland doctors (2025 update) nuffieldtrust.org.uk/resource/explo… via @Billy_Palmer_ et al & @NuffieldTrust
Further evidence that gluten is not the problem! In #IBS patients with perceived sensitivity to gluten or wheat, there is no difference in symptoms either these versus sham challenge, suggesting expectations and nocebo effect drive symptoms. thelancet.com/journals/langa…
New research - Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial thelancet.com/journals/langa… #GITwitter #MedTwitter #IBD
Let’s talk prep baby! Apologies to my fellows for embarrassing them with that joke! 🙃 But this is an important topic! ✅ Isosmotic (PEG-based) Preps • High-volume (4L): GoLYTELY, CoLyte • Low-volume (2–3L): MoviPrep, Plenvu (contain ascorbic acid) ✔️ Preferred for most…
🧵 GI Endoscopy Findings in Rheumatology – A Visual Thread Autoimmune diseases often leave visible footprints in the gut. Here are 10 key endoscopic findings linked to systemic rheumatic diseases 👇 #RheumTwitter #GastroTwitter #Endoscopy #Autoimmune #MedTwitter…
Research opportunity for UK teens with Crohn's or Colitis! We've developed a new web support programme, ASSIST-IBD to help teens live well with IBD. We need you to try it out and tell us what you think! Click link for more info: astonpsychology.eu.qualtrics.com/jfe/form/SV_5B…
GALAXI 2 and 3 trials of guselkumab maintenance in patients with Crohns disease just published 🌟Guselkumab superior to placebo and ustekinumab @TheLancet @LancetGastroHep @geteccu @sepdigestiva @aegastro ➡️ thelancet.com/journals/lance…
🎯 Extending the Half-Life of mAbs: Why It Matters in IBD In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems. 🧬 Enter Fc engineering: By tweaking the Fc region of…
Nice to see our propensity-weighted comparison of first-line vedolizumab and tofacitinib is now published. We found that the persistence & tolerability of vedolizumab were superior to tofacitinib despite comarable rates of clinical and biomarker remission academic.oup.com/ecco-jcc/advan…
You don’t have to actually worry about Pfizer’s delaying their vaccine myocarditis study until 2030. I’m a cardiologist - I’ll explain why that is the case in this thread. Biggest reason - most people already don’t trust big pharma/ gov. Why are you waiting for Pfizer…
Eight clinical trials to watch in IBD (extracted from the latest edition of Atomic IBD) 1. TL1A Inhibition — The Next Drug ClassFirst target addressing both inflammation AND fibrosis: • Tulisokibart (Merck): Phase 3 ATLAS-UC/ARES-CD ongoing • Duvakitug (Teva/Sanofi): ~48%…
A practical guide to the use of therapies in inflammatory bowel disease in the setting of chronic kidney disease. Read (open access) the guidance via bit.ly/3I9B484 #IBD #GItwitter #CKD
Unintended Consequences of Patient Portal Access jamanetwork.com/journals/jamao…
2025 @NEJM study by @bruce_sands1 et al reports efficacy and safety of anti-TL1A (Tulisokibart) in moderate-severe #UC. Notably, they evaluated patient stratification using a gene-variant machine learning algorithm. nejm.org/doi/full/10.10…
#GUTOnline @BritSocGastro #IBD #BSGGuideline #GUTGuideline reflections by @GordonMoranIBD @drmorrisgordon reflect on lessons learnt during the production of latest IBD guidelines @PhilSmithIsBack @FrontGastro_BMJ @BMJOpen_Gastro @emadelomar #BSGLive25 gut.bmj.com/content/early/…
📣 We are hiring the next #IBD clinical research 🔬 Fellow @IbdHull beta.jobs.nhs.uk/candidate/joba… Reach out for informal chat 💬
In the latest video in our partnership with @DGlaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free: nej.md/DrG19
"Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid-Responsive Acute Severe Ulcerative Colitis" now published at bit.ly/4naRVY0 #gitwitter #IBD #UC #azathioprine #tofacitinib